Validation of the RHL30 digital gene expression assay as a prognostic biomarker for relapsed Hodgkin lymphoma

Lourdes Calvente; Rosemarie Tremblay-LeMay; Wei Xu; Fong Chun Chan; Michael Hong; Tong Zhang; Ho Young Yhim; John Kuruvilla; Michael Crump; Vishal Kukreti; Anca Prica; Dean Regier; Marco A. Marra; Aly Karsan; Christian Steidl; David W. Scott; Peter Sabatini; Robert Kridel

doi:10.1111/bjh.16777

Validation of the RHL30 digital gene expression assay as a prognostic biomarker for relapsed Hodgkin lymphoma

Lourdes Calvente
, Rosemarie Tremblay-LeMay
, Wei Xu
, Fong Chun Chan
, Michael Hong
, Tong Zhang
, Ho Young Yhim
, John Kuruvilla
, Michael Crump
, Vishal Kukreti
, Anca Prica
, Dean Regier
, Marco A. Marra
, Aly Karsan
, Christian Steidl
, David W. Scott
, Peter Sabatini
, Robert Kridel

Department of Medicine

Princess Margaret Cancer Centre
University Health Network
University of Toronto
Provincial Health Services Authority

Research output: Contribution to journal › Journal article › peer-review

9 Scopus citations

Abstract

Despite continuing improvements in the management of classical Hodgkin lymphoma (cHL), relapse remains associated with a risk of lymphoma-related mortality. The biological composition of relapse tumour biopsies shows interpatient variability, which can be leveraged to design prognostic biomarkers. Here, we validated the RHL30 assay, a previously reported gene expression model in an independent cohort of 41 patients with relapsed cHL. Patients classified as high-risk by the RHL30 assay had inferior failure-free survival (FFS) after autologous stem cell transplantation (2-year FFS 41% vs. 92%, P = 0·035). The RHL30 model is a robust biomarker that risk-stratifies patients considered for autologous stem cell transplantation.

Original language	English
Pages (from-to)	864-868
Number of pages	5
Journal	British Journal of Haematology
Volume	190
Issue number	6
DOIs	https://doi.org/10.1111/bjh.16777
State	Published - 2020.09.1

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Hodgkin lymphoma
biomarker
gene expression

Access to Document

10.1111/bjh.16777

Cite this

Calvente, L., Tremblay-LeMay, R., Xu, W., Chan, F. C., Hong, M., Zhang, T., Yhim, H. Y., Kuruvilla, J., Crump, M., Kukreti, V., Prica, A., Regier, D., Marra, M. A., Karsan, A., Steidl, C., Scott, D. W., Sabatini, P., & Kridel, R. (2020). Validation of the RHL30 digital gene expression assay as a prognostic biomarker for relapsed Hodgkin lymphoma. British Journal of Haematology, 190(6), 864-868. https://doi.org/10.1111/bjh.16777

@article{d1ea5053d3e6427a89834574eb4f1fc5,

title = "Validation of the RHL30 digital gene expression assay as a prognostic biomarker for relapsed Hodgkin lymphoma",

abstract = "Despite continuing improvements in the management of classical Hodgkin lymphoma (cHL), relapse remains associated with a risk of lymphoma-related mortality. The biological composition of relapse tumour biopsies shows interpatient variability, which can be leveraged to design prognostic biomarkers. Here, we validated the RHL30 assay, a previously reported gene expression model in an independent cohort of 41 patients with relapsed cHL. Patients classified as high-risk by the RHL30 assay had inferior failure-free survival (FFS) after autologous stem cell transplantation (2-year FFS 41\% vs. 92\%, P = 0·035). The RHL30 model is a robust biomarker that risk-stratifies patients considered for autologous stem cell transplantation.",

keywords = "Hodgkin lymphoma, biomarker, gene expression",

author = "Lourdes Calvente and Rosemarie Tremblay-LeMay and Wei Xu and Chan, \{Fong Chun\} and Michael Hong and Tong Zhang and Yhim, \{Ho Young\} and John Kuruvilla and Michael Crump and Vishal Kukreti and Anca Prica and Dean Regier and Marra, \{Marco A.\} and Aly Karsan and Christian Steidl and Scott, \{David W.\} and Peter Sabatini and Robert Kridel",

note = "Publisher Copyright: {\textcopyright} 2020 British Society for Haematology and John Wiley \& Sons Ltd",

year = "2020",

month = sep,

day = "1",

doi = "10.1111/bjh.16777",

language = "English",

volume = "190",

pages = "864--868",

journal = "British Journal of Haematology",

issn = "0007-1048",

number = "6",

}

Calvente, L, Tremblay-LeMay, R, Xu, W, Chan, FC, Hong, M, Zhang, T, Yhim, HY, Kuruvilla, J, Crump, M, Kukreti, V, Prica, A, Regier, D, Marra, MA, Karsan, A, Steidl, C, Scott, DW, Sabatini, P & Kridel, R 2020, 'Validation of the RHL30 digital gene expression assay as a prognostic biomarker for relapsed Hodgkin lymphoma', British Journal of Haematology, vol. 190, no. 6, pp. 864-868. https://doi.org/10.1111/bjh.16777

TY - JOUR

T1 - Validation of the RHL30 digital gene expression assay as a prognostic biomarker for relapsed Hodgkin lymphoma

AU - Calvente, Lourdes

AU - Tremblay-LeMay, Rosemarie

AU - Xu, Wei

AU - Chan, Fong Chun

AU - Hong, Michael

AU - Zhang, Tong

AU - Yhim, Ho Young

AU - Kuruvilla, John

AU - Crump, Michael

AU - Kukreti, Vishal

AU - Prica, Anca

AU - Regier, Dean

AU - Marra, Marco A.

AU - Karsan, Aly

AU - Steidl, Christian

AU - Scott, David W.

AU - Sabatini, Peter

AU - Kridel, Robert

PY - 2020/9/1

Y1 - 2020/9/1

N2 - Despite continuing improvements in the management of classical Hodgkin lymphoma (cHL), relapse remains associated with a risk of lymphoma-related mortality. The biological composition of relapse tumour biopsies shows interpatient variability, which can be leveraged to design prognostic biomarkers. Here, we validated the RHL30 assay, a previously reported gene expression model in an independent cohort of 41 patients with relapsed cHL. Patients classified as high-risk by the RHL30 assay had inferior failure-free survival (FFS) after autologous stem cell transplantation (2-year FFS 41% vs. 92%, P = 0·035). The RHL30 model is a robust biomarker that risk-stratifies patients considered for autologous stem cell transplantation.

AB - Despite continuing improvements in the management of classical Hodgkin lymphoma (cHL), relapse remains associated with a risk of lymphoma-related mortality. The biological composition of relapse tumour biopsies shows interpatient variability, which can be leveraged to design prognostic biomarkers. Here, we validated the RHL30 assay, a previously reported gene expression model in an independent cohort of 41 patients with relapsed cHL. Patients classified as high-risk by the RHL30 assay had inferior failure-free survival (FFS) after autologous stem cell transplantation (2-year FFS 41% vs. 92%, P = 0·035). The RHL30 model is a robust biomarker that risk-stratifies patients considered for autologous stem cell transplantation.

KW - Hodgkin lymphoma

KW - biomarker

KW - gene expression

UR - https://www.scopus.com/pages/publications/85086034222

U2 - 10.1111/bjh.16777

DO - 10.1111/bjh.16777

M3 - Journal article

C2 - 32510594

AN - SCOPUS:85086034222

SN - 0007-1048

VL - 190

SP - 864

EP - 868

JO - British Journal of Haematology

JF - British Journal of Haematology

IS - 6

ER -

Validation of the RHL30 digital gene expression assay as a prognostic biomarker for relapsed Hodgkin lymphoma

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this